Background After discontinuing ruxolitinib, the outcome of patients with myelofibrosis
reportedly has been poor. The authors investigated whether disease characteristics before …

Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk …

COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase
1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with intermediate-2 or high-risk …

Ruxolitinib is a JAK1/2 inhibitor that is effective in managing symptoms and splenomegaly
related to myelofibrosis (MF). Unfortunately, many patients must discontinue ruxolitinib, at …

In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib
provided significant improvements in splenomegaly, key symptoms, and quality-of-life …

Myelofibrosis is a hematological malignancy with a median survival of approximately 5 to 7
years. Allogeneic stem cell transplantation is the only therapeutic modality that provides a …

Background Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically
significant activity in myelofibrosis. Methods In this double-blind trial, we randomly assigned …

Background Myelofibrosis (MF) is associated with a variety of burdensome symptoms and
reduced survival compared with age-/sex-matched controls. This analysis evaluated the …

Ruxolitinib is JAK1/JAK2 inhibitor with established clinical benefit in myelofibrosis (MF). We
analyzed long-term outcomes of 107 patients with intermediate-2 or high-risk MF receiving …

Despite significant improvements in the signs and symptoms of myelofibrosis (MF), and
possible prolongation of patients' survival, some have disease that is refractory to ruxolitinib …